Insight into reimbursement decision-making criteria in Bulgaria: implications for orphan drugs.

@article{Iskrov2013InsightIR,
  title={Insight into reimbursement decision-making criteria in Bulgaria: implications for orphan drugs.},
  author={Georgi G. Iskrov and Ralitsa D. Raycheva and Rumen St Stefanov},
  journal={Folia medica},
  year={2013},
  volume={55 3-4},
  pages={80-6}
}
OBJECTIVE This article's objective is to critically assess the Bulgarian legislation on health technology assessment (HTA). It analyses how innovative therapies and orphan drugs in particular would respond to the regulators' decision-making criteria for reimbursement. MATERIALS AND METHODS The study features critical analysis of current decision-making criteria for drug reimbursement in Bulgaria, as well as hypothetical scenario planning for orphan medicinal products. RESULTS The approval… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.

References

Publications referenced by this paper.
Showing 1-10 of 17 references

The limits of forecasting methods in anticipating rare events

P Goodwin, G. Wright
Technological Forecasting and Social Change • 2010
View 3 Excerpts
Highly Influenced

Methods for the comparative evaluation of pharmaceuticals

GMS health technology assessment • 2005
View 3 Excerpts
Highly Influenced

Group

IMS Consultin
AMNOG: Seven Learnings for Strategic Market Access Decisions in Germany, • 2011

Réglement intérieur de la Commission nationale d’evaluation des dispositifs medicaux et des techlogies de santé, 28.09.2010

Haute Authorité de Santé
2010

Similar Papers

Loading similar papers…